O11 Activated leukocyte cell adhesion molecule (ALCAM/CD166) is an important clinical and prognostic indicator in pancreatic cancer

Autor:	Wg. Jiang, Y Cui, Y M Yang, C Hao, Jiafu Ji, X Dong, Andrew James Sanders
Rok vydání:	2021
Předmět:	Cell adhesion molecule business.industry Pancreatic cancer Treatment outcome medicine Activated-Leukocyte Cell Adhesion Molecule Cancer research Surgery Tumor cells medicine.disease Cell adhesion business ALCAM
Zdroj:	British Journal of Surgery. 108
ISSN:	1365-2168 0007-1323
DOI:	10.1093/bjs/znab282.016
Popis:	Introduction Activated leukocyte cell adhesion molecule (ALCAM/CD166) is a cell adhesion molecule and one of the potential metastasis ‘soil’ receptors that via homotypic and heterotypic interactions, mediates cell adhesion. The present study investigated the clinical, pathological and prognostic value of ALCAM in patients with pancreatic cancer. Method Pancreatic cancer tissues (n = 223), collected immediately after surgery, were analysed for levels of the ALCAM transcripts. The expression was analysed against clinical, pathological and clinical outcome of the patients. We validated our findings with an available TCGA database (n = 117), including correlations with the ALCAM interactive partners. Result Pancreatic cancer tissues had significantly higher levels of ALCAM transcript than normal tissues (P Conclusion ALCAM/CD166 expression is aberrant in pancreatic cancer and the raised expression is an independent prognostic factor for the survival of the patients and the microvessel embolism by cancer cells. Take-home Message ALCAM is a prognostic indicator for survival and tumour embolism in pancreatic cancer
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c082b81e494f8b9729d614940116b08e https://doi.org/10.1093/bjs/znab282.016 Zobrazit plný text záznamu